<?xml version="1.0" encoding="ISO-8859-1"?>
<entity-relation-data lastUpdate="2023-03-27 16:40:31" record="21101" source="Espacenet">
	<entities>
		<entity ref="Patent21101" type="Patent">
			<semanticIdentifier>brcris::23636c7e5cbbbefe9d12477aa899c5fb</semanticIdentifier>
			<semanticIdentifier>docdb::BR102016018451A2</semanticIdentifier>
			<semanticIdentifier>epodoc::BR102016018451</semanticIdentifier>
			<semanticIdentifier>docdb::BR102016018451A</semanticIdentifier>
			<semanticIdentifier>epodoc::BR20161018451</semanticIdentifier>
			<semanticIdentifier>original::102016018451</semanticIdentifier>
			<field name="urlEspacenet" value="https://worldwide.espacenet.com/patent/search?q=102016018451"/>
			<field name="identifier.lattes" value="1480465866413262"/>
			<field name="identifier.espacenet" value="102016018451"/>
			<field name="kindCode" value="A2"/>
			<field name="title.espacenet" value="processo de obtenção e uso de nanocápsulas poliméricas contendo cilostazol como antiagregante plaquetário"/>
			<field name="title.lattes" value="Processo de obtenção e uso de nanocápsulas poliméricas contendo cilostazol como antiagregante plaquetário"/>
			<field name="depositDate" value="2016-08-11"/>
			<field name="publicationDate" value="2018-05-29"/>
			<field name="countryCode" value="BR"/>
			<field name="inventor" value="ANDRESSA NOVATSKI"/>
			<field name="inventor" value="DEBORA MARIA BORSATO"/>
			<field name="inventor" value="JESSICA MENDES NADAL"/>
			<field name="inventor" value="JOSIANE DE FATIMA GASPARI DIAS"/>
			<field name="inventor" value="MARILIS DALLARMI MIGUEL"/>
			<field name="inventor" value="MONA LISA SIMIONATTO GOMES"/>
			<field name="inventor" value="OBDULIO GOMES MIGUEL"/>
			<field name="inventor" value="PAULO VITOR FARAGO"/>
			<field name="inventor" value="SANDRA MARIA WARUMBY ZANIN"/>
			<field name="inventor" value="YASMINE MENDES PUPO"/>
			<field name="applicant" value="UNIVERSIDADE ESTADUAL DE PONTA GROSSA"/>
			<field name="applicant" value="UNIVERSIDADE FEDERAL DO PARANA"/>
			<field name="classification.ipc">
				<field name="sequence" value="1"/>
				<field name="text" value="A61K9/51AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="9"/>
				<field name="subgroup" value="51AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="2"/>
				<field name="text" value="A61K9/22AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="9"/>
				<field name="subgroup" value="22AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="3"/>
				<field name="text" value="A61K31/4709AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="K"/>
				<field name="group" value="31"/>
				<field name="subgroup" value="4709AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="4"/>
				<field name="text" value="A61P7/02AI"/>
				<field name="section" value="A"/>
				<field name="class" value="61"/>
				<field name="subclass" value="P"/>
				<field name="group" value="7"/>
				<field name="subgroup" value="02AI"/>
			</field>
			<field name="classification.ipc">
				<field name="sequence" value="5"/>
				<field name="text" value="B82Y5/00AI"/>
				<field name="section" value="B"/>
				<field name="class" value="82"/>
				<field name="subclass" value="Y"/>
				<field name="group" value="5"/>
				<field name="subgroup" value="00AI"/>
			</field>
			<field name="abstract.espacenet" value="o cilostazol é altamente recomendável o tratamento sintomático de claudicação intermitente e doença arterial periférica. no entanto, a interrupção do tratamento é, infelizmente, muito comum; estima-se que até 60% dos pacientes deixam de tomar cilostazol após 36 meses, devido aos seus efeitos colaterais e a frequência de administração. além disso, o cilostazol é classificado como um fármaco de classe ii pelo sistema de classificação biofarmacêutica e tem a solubilidade do fármaco como fator que interfere na velocidade e na extensão da absorção, o que pode comprometer a biodisponibilidade. esta patente descreve o processo de obtenção e uso de nanocápsulas de blendas de pcl-peg contendo cilostazol para diminuir a dose oral do fármaco e prolongar o efeito antiplaquetário in vivo, a fim de minimizar os inconvenientes da farmacoterapia."/>
			<field name="originatesFrom" value="62494713"/>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="docdb"/>
				<field name="country" value="BR"/>
				<field name="number" value="102016018451"/>
				<field name="kind" value="A2"/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Publication"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="BR"/>
				<field name="number" value="BR102016018451"/>
				<field name="kind" value=""/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="docdb"/>
				<field name="country" value="BR"/>
				<field name="number" value="102016018451"/>
				<field name="kind" value="A"/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="epodoc"/>
				<field name="country" value="BR"/>
				<field name="number" value="BR20161018451"/>
				<field name="kind" value=""/>
			</field>
			<field name="alternateIdentifier">
				<field name="status" value="Application"/>
				<field name="format" value="original"/>
				<field name="country" value=""/>
				<field name="number" value="102016018451"/>
				<field name="kind" value=""/>
			</field>
		</entity>
		<entity ref="Person14627" type="Person">
			<semanticIdentifier>lattes::1480465866413262</semanticIdentifier>
			<field name="identifier.lattes" value="1480465866413262"/>
			<field name="name" value="Jessica Mendes Nadal"/>
		</entity>
		<entity ref="OrgUnit11486" type="OrgUnit">
			<semanticIdentifier>brcris::97d7b7c33c80517c2049514760e7bf3f</semanticIdentifier>
			<field name="name" value="UNIVERSIDADE ESTADUAL DE PONTA GROSSA"/>
		</entity>
		<entity ref="OrgUnit11487" type="OrgUnit">
			<semanticIdentifier>brcris::c01b1b091cd49482a31899e2687d017e</semanticIdentifier>
			<field name="name" value="UNIVERSIDADE FEDERAL DO PARANA"/>
		</entity>
	</entities>
	<relations>
		<relation fromEntityRef="Patent21101" toEntityRef="Person14627" type="Inventor"/>
		<relation fromEntityRef="Patent21101" toEntityRef="OrgUnit11486" type="Applicant"/>
		<relation fromEntityRef="Patent21101" toEntityRef="OrgUnit11487" type="Applicant"/>
	</relations>
</entity-relation-data>
